Catheterbased REnal SympatheCtomy for hypErteNsion after kidneyTranplantation - CRESCENT Trial

Academisch Medisch Centrum0 个研究点目标入组 40 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•- renal graft in situ since > 6 months, measured creatinine clearance > 35 ml/min, and
•- diuresis of the native kidneys at transplant >200 ml/day or radiological evidence of residual flow in the renal arteries indicating that they are accessible for the intervention and
•- day time blood pressure >140/90 mmHg (assessed by 24-hours ambulatory measurement within 3 month prior to inclusion in the study, as is regularly performed in the nephrology outpatient clinic) while
•- treated according to National Kidney Foundation Kidney Disease Quality Outcomes Quality Initiative guidelines (2004), i.e. having been advised to minimize salt intake and using >3 antihypertensive medications in maximal tolerated dose, including a diuretic. Medications and their dosages should not have been changed since the measurement.

•- (planned) pregnancy, lactation
•- life expectancy < 1 year
•- non-functioning renal allograft in situ
•- contraindications for (relative) hypotensive episodes i.e. haemodynamically significant valvular disease, documented transient ischemic attacks or angina pectoris during relative hypotension.
•- heart failure, NYHA class III-IV; chronic Lung Disease Gold III-IV
•- major complications during previous radiological interventions (i.e. allergy to contrast agent, cholesterol embolism)
•- (reno) vascular abnormalities in any part of the catheter access (including the aortic-ileac tract) route that impede the procedure of renal denervation
•- use of vitamine K antagonists or other (non-aspirin) form of anti-coagulatory therapy with an absolute indication (i.e. that cannot be temporarily stopped)
•- implantable cardioverter defibrillator (ICD) in situ
•- planned surgery within the next six months.
•- Drugs- or alcohol abuse
•- Inability to give informed consent

发起方